Drug Profile
Research programme: immunology therapies - BioMed X/Boehringer Ingelheim
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator BioMed X; Boehringer Ingelheim
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders